Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2023 16:49 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: SIGNIFICANT NEW INVESTMENT OF NOK 144 MILLION FROM HOFSETH INTERNATIONAL INTO HBC

The board of directors (the “Board”) of Hofseth BioCare ASA ("HBC" or the "Company") has reached an agreement with Hofseth International AS (“Hofseth International”) whereby HBC will issue a new class...
November 27, 2023 05:06 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: DISCLOSURE OF LARGE SHAREHOLDING

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Reference is made to the mandatory notification of trade by Hofseth...
November 27, 2023 04:56 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE

Hofseth International AS, a close associate of Board member Roger Hofseth, has today agreed to acquire 435,207 shares in Hofseth BioCare ASA (the "Company"). The shares are purchased at a price of NOK...
November 10, 2023 02:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: THIRD QUARTER 2023 FINANCIAL REPORT

The third quarter of 2023 shows a significant growth of forty percent in sales compared to the same period last year and the increase in margins in Q2 continues. Sales revenues ended at NOK 49.9m vs...
August 25, 2023 02:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: SECOND QUARTER 2023 FINANCIAL REPORT

The second quarter of 2023 shows a 100 % growth in sales compared to the same period last year and strong increase in margins. Sales revenues ended at NOK 52.9m vs NOK 25.8m last year. The underlying...
August 17, 2023 02:58 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: SUCCESSFULLY COMPLETED SEED ROUND CAPITAL RAISE IN HBC IMMUNOLOGY LLC AT $20M VALUATION FOR THE DEVELOPMENT OF A NEW PROSTATE CANCER CO-THERAPY

HBC Immunology LLC (“HBCI” or the “Company”), a majority owned subsidiary of Hofseth BioCare ASA (“HBC”), has successfully completed the required minimum seed capital financing of approx. USD 900,000...
July 14, 2023 08:33 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Christel Elise Kanli, primary insider and CFO/COO in Hofseth BioCare ASA («HBC») has today purchased 74,000 shares in HBC at an average price of approx. NOK 2.70 per share. As a result of the...
May 30, 2023 02:40 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: ADVANCING THE TREATMENT OF PROSTATE CANCER WITH PUBLICATION OF FTH1 RESEARCH ABSTRACT AHEAD OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING

HBC is pleased to announce the online publication of its abstract titled “Antiproliferative activity of marine-derived oligopeptides combined with androgen receptor inhibition in preclinical cancer...
May 15, 2023 01:50 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: SPIN-OFF OF PROSTATE CANCER CO-TREATMENT PROJECT

Hofseth Biocare ASA ("HBC" or the "Company") today announces the decision to transfer its prostate cancer co-treatment project (the "Project") to a new US entity to be called HBC Immunology Inc....
May 12, 2023 01:56 ET | Source: Hofseth Biocare ASA

Hofseth BioCare ASA: FIRST QUARTER 2023 FINANCIAL REPORT

The first quarter of 2023 shows a very good development for HBC. Revenues came in at NOK 44m vs NOK 30m last year, a growth of 48 % YoY and 32 % QoQ. The underlying growth we are seeing is coming from...